NBTX
Nanobiotix SA
$
7.400
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
7.620
Open
7.620
VWAP
7.53
Vol
3.53K
Mkt Cap
705.74M
Low
6.970
Amount
26.59K
EV/EBITDA(TTM)
--
Total Shares
47.11M
EV
621.06M
EV/OCF(TTM)
--
P/S(TTM)
--
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Show More
2 Analyst Rating
14.86% Upside
Wall Street analysts forecast NBTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBTX is 8.50 USD with a low forecast of 8.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
14.86% Upside
Current: 7.400
Low
8.00
Averages
8.50
High
9.00
14.86% Upside
Current: 7.400
Low
8.00
Averages
8.50
High
9.00
Guggenheim
Michael Schmidt
Strong Buy
Maintains
$12 → $8
2025-04-04
Reason
Guggenheim
Michael Schmidt
Price Target
$12 → $8
2025-04-04
Maintains
Strong Buy
Reason
Guggenheim lowered the firm's price target on Nanobiotix to $8 from $12 and keeps a Buy rating on the shares. After the company reported FY24 earnings consistent with prior disclosures, the firm is updating its model to reflect second half results and remove assumptions for recurrent/metastatic head and neck squamous cell carcinoma.
Guggenheim
Michael Schmidt
Strong Buy
Initiates
$12
2024-08-28
Reason
Guggenheim
Michael Schmidt
Price Target
$12
2024-08-28
Initiates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Nanobiotix SA (NBTX.O) is -9.48, compared to its 5-year average forward P/E of -5.65. For a more detailed relative valuation and DCF analysis to assess Nanobiotix SA 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-5.65
Current PE
-9.48
Overvalued PE
-3.34
Undervalued PE
-7.96
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-4.24
Current EV/EBITDA
-8.05
Overvalued EV/EBITDA
-2.29
Undervalued EV/EBITDA
-6.20
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
71.71
Current PS
19.86
Overvalued PS
163.80
Undervalued PS
-20.38
Financials
Annual
Quarterly
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 1048.78% over the last quarter.
Sold
0-3
Months
1.9M
Volume
1
3-6
Months
161.0K
Volume
1
6-9
Months
289.0K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
1.6M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
NBTX News & Events
Events Timeline
2025-07-07 (ET)
2025-07-07
16:18:40
Nanobiotix announces regulatory harmonization, new patent for JNJ-1900
2025-03-17 (ET)
2025-03-17
16:23:59
Nanobiotix amends global licensing agreement with Janssen Pharmaceutica
2025-01-21 (ET)
2025-01-21
04:32:41
Nanobiotix doses first patient in CONVERGE study
Sign Up For More Events
Sign Up For More Events
News
9.0
07-07NewsfilterNANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)
7.0
05-21NewsfilterNanobiotix Provides First Quarter 2025 Operational and Financial Update
1.0
05-12NewsfilterNanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
Sign Up For More News
People Also Watch
VTYX
Ventyx Biosciences Inc
2.630
USD
-0.38%
TDTH
Trident Digital Tech Holdings Ltd
0.820
USD
-8.79%
FRGE
Forge Global Holdings Inc
22.190
USD
-0.85%
INMB
INmune Bio Inc
2.420
USD
+0.83%
WHG
Westwood Holdings Group Inc
18.320
USD
+5.29%
HOFT
Hooker Furnishings Corp
9.580
USD
+3.01%
VERU
Veru Inc
3.170
USD
-11.70%
SGHT
Sight Sciences Inc
4.250
USD
+3.16%
MPAA
Motorcar Parts of America Inc
14.520
USD
+5.14%
ALTO
Alto Ingredients Inc
1.040
USD
+2.97%
FAQ
What is Nanobiotix SA (NBTX) stock price today?
The current price of NBTX is 7.4 USD — it has increased 0.68 % in the last trading day.
What is Nanobiotix SA (NBTX)'s business?
What is the price predicton of NBTX Stock?
What is Nanobiotix SA (NBTX)'s revenue for the last quarter?
What is Nanobiotix SA (NBTX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Nanobiotix SA (NBTX)'s fundamentals?
How many employees does Nanobiotix SA (NBTX). have?